Pharma BD Deal Intelligence
Hostile-turned-friendly mega-merger built global scale but integration proved complex
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sanofi acquired Aventis for $73.5B (EUR 54.5B) after three-month takeover battle.
Resolving anticompetitive concerns, FTC clears Sanofi-Synthelabo's acquisition of Aventis subject to conditions regarding colorectal cancer drug and insulin…
Sanofi-Synthelabo filed a prospectus supplement for the exchange offer to acquire outstanding shares of Aventis SA in a combined stock-and-cash transaction.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi-Synthelabo acquired Aventis for approximately EUR 55.2 billion ($65 billion) after an initial hostile bid of EUR 47.8 billion was rejected. The revised friendly offer comprised five Sanofi shares for each Aventis share plus EUR 120 in cash, creating the world's third-largest pharmaceutical company.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Synthelabo SA / Aventis SA (this deal) | 2004 | $65.0B | 80 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2004 deals · Cardiovascular deals